Multiparameter calibration of a natural history model of cervical cancer

American Journal of Epidemiology

Volumn 166, Issue 2, 2007, Pages 137-150

  Kim, Jane J ^a   Kuntz, Karen M ^a   Stout, Natasha K ^a   Mahmud, Salaheddin ^b   Villa, Luisa L ^c   Franco, Eduardo L ^b   Goldie, Sue J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

Author keywords

Calibration; Computer simulation; Human papillomavirus 16; Human papillomavirus 18; Natural history; Papillomavirus vaccines; Uterine cervical neoplasms

Indexed keywords

CALIBRATION; CANCER; COMPUTER SIMULATION; DISEASE INCIDENCE; DISEASE PREVALENCE; EPIDEMIOLOGY; VIRUS;

AGE DISTRIBUTION; ANAMNESIS; ARTICLE; BRAZIL; CALIBRATION; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RISK; HIGH RISK PATIENT; HUMAN; INFECTION RISK; LONGITUDINAL STUDY; MATHEMATICAL MODEL; PRECANCER; PREVALENCE; UTERINE CERVIX CANCER; WART VIRUS; ADOLESCENT; ADULT; AGED; BIOLOGICAL MODEL; CHILD; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; MIDDLE AGED; MONTE CARLO METHOD; UTERINE CERVIX CARCINOMA IN SITU; VIROLOGY; VIRUS INFECTION;

BRAZIL; SOUTH AMERICA;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS - 16; HUMAN PAPILLOMAVIRUS - 18; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

PAPILLOMA VIRUS VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; BRAZIL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHILD; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE;

EID: 34447622185     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwm086     Document Type: Article

References (73)

1. Franco EL, Rohan TE, Villa LL. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 1999;91:506-11.
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
3. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
4. Food and Drug Administration. FDA licenses new vaccine for prevention of cervical cancer and other diseases in females caused by human papillomavirus. Press release, 2006. (http://www.fda.gov/bbs/topics/NEWS/2006/NEW01385.html).
5. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al. Costeffectiveness of cervical cancer screening in five developing countries. N Engl J Med 2005;353:2158-68.
6. Goldie SJ, Goldhaber-Fiebert JD, Garnett GP. Chapter 18: public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. Vaccine 2006;24(suppl 3):S155-63.
7. Garnett GP, Kim JJ, French K, et al. Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006;24(suppl 3):S178-86.
8. Franco E, Villa L, Rohan T, et al. Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Ludwig-McGill Study Group. Rev Panam Salud Publica 1999;6:223-33.
9. Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000;92:464-74.
10. Molano M, Posso H, Weiderpass E, et al. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer 2002;87:324-33.
11. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366:991-8.
12. Clifford GM, Rana RK, Franceschi S, et al. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1157-64.
13. Clifford GM, Smith JS, Aguado T, et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003;89:101-5.
14. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a metaanalysis. Br J Cancer 2003;88:63-73.
15. Waterhouse J, Muir C, Correa P, et al, eds. Cancer incidence in five continents. Vol III. Lyon, France: International Agency for Research on Cancer, 1976. (IARC scientific publication no. 15).
16. Parkin DM, Whelan SL, Ferlay J, et al, eds. Cancer incidence in five continents. Vol VIII. Lyon, France: International Agency for Research on Cancer, 2002. (IARC scientific publication no. 155).
17. Trottier H, Mahmud S, Costa MC, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2006;15:1274-80.
18. Munoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004;190:2077-87.
19. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-40.
20. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
21. Liu T, Soong SJ, Alvarez RD, et al. A longitudinal analysis of human papillomavirus 16 infection, nutritional status, and cervical dysplasia progression. Cancer Epidemiol Biomarkers Prev 1995;4:373-80.
22. Sun XW, Kuhn L, Ellerbrock TV, et al. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997;337:1343-9.
23. McCrory D, Mather D, Bastian L, et al. Evaluation of cervical cytology. Rockville, MD: Agency for Health Care Policy and Research, 1999. (Evidence report/technology assessment no. 5).
24. Myers ER, McCrory DC, Nanda K, et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000;151:1158-71.
25. Londesborough P, Ho L, Terry G, et al. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer 1996;69:364-8.
26. Syrjanen K, Kataja V, Yliskoski M, et al. Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System. Obstet Gynecol 1992;79:675-82.
27. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71.
28. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993;12:186-92.
29. Melnikow J, Nuovo J, Willan AR, et al. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998;92:727-35.
30. Ho GY, Kadish AS, Burk RD, et al. HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia. Int J Cancer 1998;78:281-5.
31. Hopman EH, Rozendaal L, Voorhorst FJ, et al. High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy. BJOG 2000;107:600-4.
32. Rozendaal L, Walboomers JM, van der Linden JC, et al. PCRbased high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer 1996;68:766-9.
33. Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000;283:1031-7.
34. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-8.
35. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354:20-5.
36. Remmink AJ, Walboomers JM, Helmerhorst TJ, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 1995;61:306-11.
37. Ries LA, Eisner MP, Kosary CL, et al, eds. SEER cancer statistics review, 1975-2001. Bethesda, MD: National Cancer Institute, 2004. (http://seer.cancer. gov/csr/1975_2001/, 2004).
38. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995;141:680-9.
39. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132:810-19.
40. Wright TC Jr, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004;103:304-9.
41. Bergeron C, Jeannel D, Poveda J, et al. Human papillomavirus testing in women with mild cytologic atypia. Obstet Gynecol 2000;95:821-7.
42. Ferris DG, Wright TC Jr, Litaker MS, et al. Triage of women with ASCUS and LSIL on Pap smear reports: management by repeat Pap smear, HPV DNA testing, or colposcopy? J Fam Pract 1998;46:125-34.
43. Ferris DG, Wright TC Jr, Litaker MS, et al. Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL. J Fam Pract 1998;46:136-41.
44. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 2002;287:2382-90.
45. Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004;103:619-31.
46. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180:1415-23.
47. Schlecht NF, Platt RW, Duarte-Franco E, et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003;95:1336-43.
48. Schlecht NF, Platt RW, Negassa A, et al. Modeling the time dependence of the association between human papillomavirus infection and cervical cancer precursor lesions. Am J Epidemiol 2003;158:878-86.
49. Sadeghi SB, Sadeghi A, Robboy SJ. Prevalence of dysplasia and cancer of the cervix in a nationwide, planned parenthood population. Cancer 1988;61:2359-61.
50. Kotloff KL, Wasserman SS, Russ K, et al. Detection of genital human papillomavirus and associated cytological abnormalities among college women. Sex Transm Dis 1998;25:243-50.
51. Bauer HM, Hildesheim A, Schiffman MH, et al. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. Sex Transm Dis 1993;20:274-8.
52. Ley C, Bauer HM, Reingold A, et al. Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst 1991;83:997-1003.
53. Melkert PW, Hopman E, van den Brule AJ, et al. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer 1993;53:919-23.
54. Mount SL, Papillo JL. A study of 10,296 pediatric and adolescent Papanicolaou smear diagnoses in northern New England. Pediatrics 1999;103:539-45.
55. Lawson HW, Lee NC, Thames SF, et al. Cervical cancer screening among low-income women: results of a national screening program, 1991-1995. Obstet Gynecol 1998;92:745-52.
56. Lorenzato F, Ho L, Terry G, et al. The use of human papillomavirus typing in detection of cervical neoplasia in Recife (Brazil). Int J Gynecol Cancer 2000;10:143-50.
57. Rabelo-Santos SH, Zeferino L, Villa LL, et al. Human papillomavirus prevalence among women with cervical intraepithelial neoplasia III and invasive cervical cancer from Goiania, Brazil. Mem Inst Oswaldo Cruz 2003;98:181-4.
58. Eluf-Neto J, Booth M, Munoz N, et al. Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer 1994;69:114-19.
59. Goldie SJ, Kuhn L, Denny L, et al. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001;285:3107-15.
60. Yang BH, Bray FI, Parkin DM, et al. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer 2004;109:418-24.
61. Ho GY, Studentsov Y, Hall CB, et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 2002;186:737-42.
62. Salomon JA, Weinstein MC, Hammitt JK, et al. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 2002;156:761-73.
63. Cancre N, Tall A, Rogier C, et al. Bayesian analysis of an epidemiologic model of Plasmodium falciparum malaria infection in Ndiop, Senegal. Am J Epidemiol 2000;152:760-70.
64. Craig BA, Fryback DG, Klein R, et al. A Bayesian approach to modelling the natural history of a chronic condition from observations with intervention. Stat Med 1999;18:1355-71.
65. Stout NK, Fryback DG, Rosenberg MA, et al. Construction, verification, and calibration of a discrete event simulation model of breast cancer epidemiology inWisconsin. (Abstract). Presented at the 24th Annual Meeting for the Society for Medical Decision Making, Baltimore, Maryland, October 19-23, 2002.
66. Knudsen AB, Weinstein MC, Kuntz KM. Modeling unobserved processes: a likelihood-based approach to model calibration. (Abstract). Presented at the 25th Annual Meeting for the Society for Medical Decision Making, Chicago, Illinois, October 18-22, 2003.
67. Kennedy MC, O'Hagan A. Bayesian calibration of computer models. J R Stat Soc (B) 2001;63:425-64.
68. Andradottir S, Bier VM. Applying Bayesian ideas in simulation. Simul Pract Theory 2000;8:253-80.
69. Franco EL. Measurement errors in epidemiological studies of human papillomavirus and cervical cancer. IARC Sci Publ 1992:181-97.
70. Franco EL. Statistical issues in human papillomavirus testing and screening. Clin Lab Med 2000;20:345-67.
71. Nelder JA, Mead R. A simplex method for function minimization. Comput J 1965;7:303-33.
72. Hunink MGM, Glasziou P, Siegel JE, et al. Decision making in health andmedicine: integrating evidence and values.Chapter 11. New York, NY: Cambridge University Press, 2001.
73. Franco EL, Cuzick J, Hildesheim A, et al. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006;24(suppl 3):S171-7.